ASTELLAS PHARMA
ET 158 RUE DANTON 26 QUAI CHARLES PASQUA 92300
LEVALLOIS PERRET
ILE DE FRANCE France
Pfizer aims for wider use of PARP drug in prostate cancer with new data
While sales of Talzenna, which Pfizer acquired in a $14 billion deal, have been “negligible” so far, the new results should justify use in earlier lines of care, one analyst said.
Source: BioPharma Dive Mar 19, 2026
Will Linzess Continue to Aid IRWD's Top Line in 2026 After a Soft Q4?
Ironwood sees Linzess rebounding in 2026 despite soft Q4 results, helped by strong prescription demand and improved net pricing.
Source: Zacks Mar 6, 2026
Pfizer Inc. (PFE) and Astellas Pharma Announce Positive Results From the Phase 3 EV-304 Clinical Trial for PADCEVTM
Pfizer Inc. (NYSE:PFE) is one of the best cheap stocks under $50 to buy right now. Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. announced on February 27 positive results from the Phase 3 EV-304 clinical trial for PADCEVTM, a Nectin-4 directed antibody-drug conjugate, in combination with Keytruda®, a PD-1 inhibitor, in patients with muscle-invasive bladder
Source: Insider Monkey Mar 1, 2026
Vir Biotechnology Astellas Deal Puts VIR-5500 And Valuation In Focus
Vir Biotechnology (NasdaqGS:VIR) announced a global collaboration with Astellas Pharma to develop and commercialize VIR-5500 for metastatic castration-resistant prostate cancer. The agreement includes substantial upfront and near-term funding to support VIR-5500 and broader pipeline development. Positive Phase 1 data for VIR-5500 reported promising anti-tumor activity and safety in prostate cancer patients. The deal marks Vir's entry into high-profile immuno-oncology partnerships and...
Source: Simply Wall St. Feb 28, 2026
Merck Says Keytruda Plus Padcev Decreases Risk of Death in Bladder Cancer Trial
Merck (MRK) said Friday that a phase 3 trial showed Keytruda plus Padcev decreased the risk of event
Source: MT Newswires Feb 27, 2026
Vir climbs on Astellas deal, study results for ‘masked’ T cell engager
According to one analyst, the alliance and early data “validate” the oncology work of Vir, which was once purely an infectious disease specialist before changing course.
Source: BioPharma Dive Feb 24, 2026
- Laboratory chemicals
- Apparatus based on the use of x-rays or of alpha, beta or gamma radiations, for medical, surgical, dental or veterinary uses
- Articles of apparel and clothing accessories, of leather
- Glass ampoules
- Ampoules of glass
- Surgical drapes
- Dental instruments and appliances, other than those of 9018
- Elastomeric seals, gaskets and similar joints of cellular rubber
- Parts and accessories for ophthalmic instruments or appliances
- Articles and equipment for general physical exercise
- Other parts and accessories of vehicles of 8701 to 8705
- Cameras
- Projection screens
- Contact lenses
- Denim shirts and trousers
- Rubber bands
- Printed books, brochures and similar printed matter, in single sheets
- Other seats, with metal frames
- Ink cartridges
- Pumps for liquids, whether or not fitted with a measuring device, other than those of 8413
- Prefabricated buildings of wood
- Parts of industrial trucks
- Washing machines
- Other taps, cocks, valves and similar appliances, for pipes, boiler shells, tanks, vats or the like, including pressure reducing valves and thermostatically controlled valves
- Other panels, boards, tiles, blocks and similar articles of vegetable fiber
- Packings, glands and similar packing materials of rubber or plastics
- Other furniture
- Other laboratory, chemical or other technical glassware
- Other adhesive paper and paperboard
- Pens
- Pharmaceuticals
- Antibiotics
- Biotechnology products
- Vitamins
- Sterile
- Injectable
- Generic drugs
- Branded drugs
- Otc drugs
- Prescription drugs
- Biologics
- Hormones
- Medical devices
- Diagnostics
- Laboratory equipment
- Research chemicals
- Specialty chemicals
- Pharmaceutical intermediates
- Fine chemicals
- Pharmaceutical services
- Clinical research services
- Pharmacovigilance services
- Regulatory affairs services
- Healthcare consulting services
- Market research services
- Pharmaceutical marketing services
- Sales and distribution services
- Pharmaceutical logistics services
- Pharmaceutical packaging services
- Pharmaceutical manufacturing services
IndexBox is not affiliated with, associated with, or endorsed by this company in any way. The information provided on this page, including company details, is solely for informational purposes. IndexBox makes no representations or warranties about the accuracy or completeness of the information provided.
All data and information is provided “as is” for informational purposes only, and is not intended for trading purposes or financial, investment, tax, legal, accounting or other advice. Please consult your broker or financial representative to verify pricing before executing any trade. IndexBox is not an investment adviser, financial adviser or a securities broker. None of the data and information constitutes investment advice nor an offering, recommendation or solicitation by IndexBox to buy, sell or hold any security or financial product, and IndexBox makes no representation (and has no opinion) regarding the advisability or suitability of any investment.